Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic
- Centre de Recherche de Biochimie Macromoléculaire, UMR5235, 1919 Route de Mende, Montpellier 34293, France
- Correspondence should be addressed to D P Xirodimas; Email: dimitris.xirodimas{at}crbm.cnrs.fr
Abstract
Post-translational modification of proteins with ubiquitin and ubiquitin-like molecules (UBLs) controls a vast if not every biological process in the cell. It is not surprising that deregulation in ubiquitin and UBL signalling has been implicated in the pathogenesis of many diseases and that these pathways are considered as major targets for therapeutic intervention. In this review, we summarise recent advances in our understanding of the role of the UBL neural precursor cell expressed developmentally downregulated-8 (NEDD8) in cancer-related processes and potential strategies for the use of NEDD8 inhibitors as chemotherapeutics.
- Revision received 19 November 2014
- Accepted 11 December 2014
- Made available online as an Accepted Preprint 11 December 2014
- © 2015 Society for Endocrinology
